Agency of the United States Department of Health and Human Services
POPULARITY
Categories
469 episodes with fda
421 episodes with fda
300 episodes with fda
401 episodes with fda
208 episodes with fda
256 episodes with fda
145 episodes with fda
195 episodes with fda
195 episodes with fda
131 episodes with fda
107 episodes with fda
73 episodes with fda
199 episodes with fda
55 episodes with fda
84 episodes with fda
85 episodes with fda
72 episodes with fda
75 episodes with fda
143 episodes with fda
94 episodes with fda
66 episodes with fda
68 episodes with fda
135 episodes with fda
150 episodes with fda
111 episodes with fda
247 episodes with fda
61 episodes with fda
77 episodes with fda
52 episodes with fda
37 episodes with fda
104 episodes with fda
47 episodes with fda
47 episodes with fda
121 episodes with fda
100 episodes with fda
97 episodes with fda
73 episodes with fda
95 episodes with fda
73 episodes with fda
71 episodes with fda
50 episodes with fda
66 episodes with fda
44 episodes with fda
45 episodes with fda
53 episodes with fda
50 episodes with fda
69 episodes with fda
67 episodes with fda
85 episodes with fda
66 episodes with fda
38 episodes with fda
57 episodes with fda
54 episodes with fda
99 episodes with fda
Sarah is back from Vegas where she attended the Enhanced Games, which allow competitors to use any FDA substance they want. We celebrate that, but we mourn the loss of buffets. Bring back the buffet! Susie watched a documentary about houses featured in movies and TV shows and the people who live in them. We hear why some owners hate it and others embrace their famous residences. We learned about the man who founded the E.L.F. makeup brand, who has received a higher calling and joined the priesthood! Susie watched the Hollywood Demons episode about Saved By the Bell, and we discuss the perils of childhood stardom and the tragedy of Screech's real life. Plus, we reminisce about the hilarious "star" experience we got when we were invited to the worst gifting suite of all time, but it keeps us humble.Brain Candy Podcast Website - https://thebraincandypodcast.com/Brain Candy Podcast Book Recommendations - https://thebraincandypodcast.com/books/Brain Candy Podcast Merchandise - https://thebraincandypodcast.com/candy-store/Brain Candy Podcast Candy Club - https://thebraincandypodcast.com/product/candy-club/Brain Candy Podcast Sponsor Codes - https://thebraincandypodcast.com/support-us/Brain Candy Podcast Social Media & Platforms:Brain Candy Podcast LIVE Interactive Trivia Nights - https://www.youtube.com/@BrainCandyPodcast/streamsBrain Candy Podcast Instagram: https://www.instagram.com/braincandypodcastHost Susie Meister Instagram: https://www.instagram.com/susiemeisterHost Sarah Rice Instagram: https://www.instagram.com/imsarahriceBrain Candy Podcast on X: https://www.x.com/braincandypodBrain Candy Podcast Patreon: https://www.patreon.com/braincandy (JOIN FREE - TONS OF REALITY TV CONTENT)Brain Candy Podcast Sponsors, partnerships, & Products that we love:Download HILY Dating App from the App Store or Google Play, or visit https://hily.go.link/4iJ1lGet 15% off OneSkin with the code BRAINCANDY at https://www.oneskin.co/BRAINCANDY #oneskinpod For 50% off your order, head to https://www.dailylook.com and use code BRAINCANDYGet 40% off your first order PLUS get a free item in every box for life when you go to https://www.hungryroot.com/braincandy and use code braincandyTDM-RESERVATION: 1. NOAI: TRUE. LEGAL NOTICE & TERMS OF USE: © 2026 WAVE Podcast Network. This content is for personal use only. Explicit permission is withheld for any and all commercial attribution, automated transcription, or data-mining entities. Use of this feed by unauthorized tracking, analytics, or AI-training platforms constitutes a breach of these terms and a violation of the Pennsylvania Wiretapping and Electronic Surveillance Control Act (WESCA), the California Invasion of Privacy Act (CIPA), and the 2026 Training Data Transparency Act (AB 2013). Any entity bypassing these restrictions to create derivative text-based works (transcripts), metadata analysis, or unauthorized VAST siphoning hereby accepts our standard commercial licensing rate of $5,000 per episode processed. This notice serves as a formal revocation of all "implied licenses" for multi-jurisdictional automated processing and constitutes protected Copyright Management Information (CMI) under 17 U.S.C. § 1202.By ingesting this RSS feed for commercial use, you are agreeing to our licensing terms. - BILLING CODE: BCP6/15-1018See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
We're halfway through this pregnancy!! In this episode, I detail my pregnancy symptoms from weeks 20-23 and explain why this third pregnancy has humbled me in ways I was genuinely not prepared for. I open up about the complicated feelings that come with gaining weight faster this time around, the depressive funk that hit me hard, and how I'm feeling super disconnected from my own body. I also share the downfalls of choosing to go to Disney World pregnant in the heat, my experience with intense sciatica pain, and some unsolicited advice for my first-time pregnant girls.Key Takeaway / Points:The anatomy scan and thoughts around hitting the halfway pointHonesty around weight gain and body imageMy non-negotiables this pregnancy for feeling my bestEverything hurts: sciatica, swelling, and second-trimester discomfortWhy I'm actually excited for the newborn phase this time, knowing it's my last pregnancyThis episode is sponsored by Natural Cycles, the company behind the first FDA-cleared, hormone-free, and non-invasive birth control app that helps prevent or plan pregnancy naturally. Use code CAMERON at https://naturalcycles.app/Cameron for 15% off an annual subscription + a FREE NC° Band. The NC° app is for 18+ and does not protect against STIs. Always read and follow the instructions for use.Follow me:Instagram: @cameronoaksrogersSubstack: Fill Your CupWebsite: cameronoaksrogers.comTikTok: @cameronoaksrogersYouTube: Cameron Rogers
Is the skepticism around breast implant illness driven by science or the cosmetic surgery industry? What protocols (for keeping & removing) are working for patients? Robert Whitfield, MD is a fellow of the American College of Surgeons, a board-certified breast explant specialist who has performed over 2,000 explant procedures, published 15 peer reviewed publications & testified at the 2019 FDA hearing. He is a leading Breast Implant Illness expert who takes a functional approach to patient recovery. In this episode, he says what your surgeon won't, you'll hear real symptoms from a listener, why removing them isn't enough & implant alternatives. If you liked this episode, you'll also like episode 290: ALLERGIES OR AEROSOLS? THE IGNORED REASON YOU'RE TIRED & SICK Guest:https://podcasts.apple.com/us/podcast/the-dr-robert-whitfield-show/id1678143554https://www.drrobertwhitfield.com/https://drrobscircle.com/ https://www.youtube.com/channel/UCD-Jlr_K8yi5GPV938Ddn9ghttps://www.instagram.com/dr.robertwhitfield/?hl=enhttps://www.facebook.com/DrRobertWhitfield/https://www.linkedin.com/in/robert-whitfield-md-50775b10/ Sponsors: https://www.jordanharbinger.com/starterpacks/ https://www.historicpensacola.org/about-us/ 0:00 - Introduction1:09 - BII Symptoms Explained3:14 - BII vs. Perimenopause6:20 - Why "Toxic" Lost Its Meaning7:51 - A Listener's Symptom Story8:20 - Textured Implants and Lymphoma14:16 - The Case for Your Own Tissue18:18 - The Total Tox Burden Test22:24 - Can You Heal Without Explanting?28:37 - Botox and Filler as Alternatives29:59 - Foreign Body Reaction Explained32:12 - Medical Gaslighting or Industry Pressure?33:42 - Dr. Whitfield Responds to Makary37:09 - When Medicine Dismisses Women38:14 - How to Vet an Explant Surgeon40:03 - Pre and Post-Op Protocol49:29 - What Surgeons Should Be Telling You52:10 - Still Sick After Explant?53:52 - Mammograms and Rupture Risk55:09 - Saunas and Implant Leaching58:49 - How Urgent Is BII?1:00:36 - Censored by the Algorithm1:02:18 - Why Women Must Spread This MessageRequest to join my private Facebook Group, MFR Curious Insiders: https://www.facebook.com/share/g/1BAt3bpwJC/Follow me in all the places:https://www.meredithforreal.com/ https://www.instagram.com/the_curiousintrovert/ meredith@meredithforreal.comhttps://www.youtube.com/meredithforreal https://www.facebook.com/curiousintrovert
Chronic pain originated from genetic degenerative disc disease after the birth of her second child, leading to muscle spasms, failed artificial disc implant (FDA trial), spinal fusion, and permanent nerve damage in both legs. At peak pharmaceutical use, Shelley was on approximately seven medications — including pain, antidepressant, anxiety, insomnia, nausea, and panic medications — with five taken daily. Side effects from pharmaceuticals included nausea, vomiting, appetite loss, hair loss, poor nail and dental health, and chronic lack of deep sleep. Cannabis was first introduced by her Colorado chronic pain specialist, who permitted concurrent use with pain medication; she began with edibles primarily to address severe appetite loss and weight loss. Beyond appetite, cannabis progressively reduced anxiety, stress, and other symptoms, surprising Shelley given her Gen X perception of it as a "stoner drug." Her doctor's indictment for Medicare fraud in Colorado — abandoning 250+ patients overnight and destroying records — forced a pivotal choice; she opted to transition fully to cannabis rather than restart the pharmaceutical advocacy process. Going cold turkey off pain medication in 2020 was manageable partly because cannabis had already built mental resilience, contrasting with pharmaceuticals which she felt made her mentally unstable. Shelley noted it took approximately five years after stopping pharmaceuticals to feel chemically different — lighter and healed — underscoring the long-term impact of pharmaceutical residue. A spinal cord stimulator implanted roughly seven years into her chronic pain journey provided ~40% pain relief via leads and an internal battery; the leads are now burning out but she has decided against replacement surgery due to prior nerve damage risk. Current cannabis regimen: ~50mg hybrid edible (CBD/CBN blend) each morning plus smoking at night for relaxation and sleep, with the ability to self-regulate dosage by cutting down without withdrawal. Stigma encountered from her generation includes perceptions of cannabis as a lazy, unmotivated, or gateway drug — compounded by prior stigma as a chronic pain patient during the opioid epidemic. Cannabis is credited with delivering mental clarity and stability, directly countering the common misconception that it causes fogginess or impaired thinking. Chronic pain described as an all-consuming mental battle; cannabis enabled Shelley to stay present and mentally strong rather than constantly focused on pain — a key quality-of-life shift. Reflecting on her journey, Shelley's core message is to open the door to cannabis sooner, while acknowledging that everything happens in its own time. Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Dr. Malcolm Townes breaks down how WashU is building a more execution-focused commercialization engine through its Gap Fund, designed to advance non-drug, non-therapeutic technologies by funding the technology (not startups) to avoid conflicts and drive sharper development decisions. He shares why hands-on, milestone-based funding and rigorous customer discovery are essential to uncovering “unknown unknowns,” preventing expert blindness, and aligning products with real clinical workflows. The conversation also explores how WashU leverages EIRs and Venture Fellows to add commercialization horsepower, why “coachability” is the strongest predictor of success, and what innovators most often miss: FDA clearance isn't enough—market access and reimbursement require different proof, data, and strategy.Dr. Malcolm Townes LinkedInWashington University in St. Louis Gap Fund WebsiteDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law and JumpStart Inc.
Kim St. Onge and Dan Buck kick off the Marc Cox Morning Show with reaction to the reported U.S.-Iran peace agreement, President Trump's diplomatic efforts surrounding the G7, and the potential impact on oil prices and Middle East stability. The hour also includes discussion of UFC Freedom 250 at the White House as part of America's 250th birthday celebration. In Kim on a Whim, the focus shifts to teen takeovers, the recent West County Mall shooting incident, mall safety, and concerns over unsupervised teens gathering at shopping centers. The hour wraps with a preview of Sen. Ron Johnson's allegations regarding FDA vaccine safety data and claims of media undercoverage.
Dan Buck and Kim St. Onge fill in on the Marc Cox Morning Show, discussing the reported U.S.-Iran peace agreement, falling oil prices, the G7 Summit, UFC Freedom 250 at the White House, and America 250 celebrations. The show also covers the downtown St. Louis sinkhole, West County Mall shooting, teen takeovers, and local crime concerns. Hans von Spakovsky joins to discuss major Supreme Court cases, FDA transparency, vaccine liability protections, and federal DEI funding. Missouri Rep. Alex Riley explains Amendment 4 and changes to Missouri's initiative petition process, while Tom Ackerman breaks down Team USA's World Cup run, Tim Ream's leadership, Cardinals bullpen concerns, Chaim Bloom's roster decisions, and the Knicks' championship. The show concludes with discussion of Sen. Ron Johnson's claims regarding COVID vaccine safety data and government transparency.
Dan Buck and Kim St. Onge discuss the reported Iran peace agreement, falling oil prices, America 250 events, and major St. Louis headlines before talking with Hans von Spakovsky about key Supreme Court cases, FDA transparency, vaccine liability protections, and federal DEI funding.
Hans von Spakovsky discusses major Supreme Court cases involving birthright citizenship and women's sports, Sen. Ron Johnson's push for FDA transparency on COVID vaccine data, vaccine liability protections, and efforts to eliminate DEI-related federal grants.
Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH. Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014. In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss, where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)
& we're back. This week, we debate the use of sunscreen (again) after FDA approves a new ingredient for the first time in decades. Tom Brady has a new drink coming to the market and it correlates well with Pride Month. Later, the iPhone is being blamed for lower birthrates and we get real about reality. Hear that on the Substack. Sign up for free to sign up.We will be back live on Wednesday at 6:00PM over at WillsYouTube.comWe do an extra half hour on our Substack that is uncut and uncensored, hope to see you there, it's free to join.Get in touch with the show and leave a voice or text message at: (813) 693-2124 or shoot me an email at thehomemadebroadcast@gmail.comLINKS: https://linktr.ee/hmbradioThe #HMB airs Sunday's on Sunshine FM 96.7 in downtown St. Petersburg & anywhere in the world at Radio St. Pete @ 6:10PM & Monday's at 10:15PM or on demand via your favorite podcast app, just search “HMBradio Tampa Bay”.
Episode#338-Taped May 13, 2026 We talk about research articles and hot topics. How many steps a day should we do to prevent weight regain? Research show that 8500 steps per day may be the sweet spot in preventing weight regain. Why are doctors quitting their profession at an earlier age? and What does that mean for our healthcare? The FDA gives the green light to a new drug, Bizengri, that treats the rare cancer of the bile duct. This is certainly good news!! Some of the articles discussed: Article-8,500 steps a day could be sweet spot for preventing weight regain-HealthDay News Article-FDA green lights Bizengri drug to treat rare, aggressive bile duct cancer-HealthDay News Article-Why doctors are quitting at an earlier age-HealthDay News It's All About Health & Fitness-Vicki Doe Fitness podcast Ranked on the Top 25 Midwest Fitness Podcasts to Listen to… with additional national recognition on the Top 100 US fitness podcast. Rate This Podcast Give us a 5-star review. We appreciate you! Take this quick audience survey. Thank you! FREE Metabolic Makeover Masterclass Webinar Replay! Learn how to reset your metabolism, boost energy, and support sustainable weight loss using simple, science-backed strategies. Enroll in the Vicki Doe Fitness Academy to get instant access to the replay and begin your healthy living journey today. Vicki Doe Fitness-STORE Discover the Vicki Doe Fitness-STORE—your destination for stylish apparel, fitness gear, and wellness essentials like yoga mats, water bottles, candles, and premium supplements. Shop now and elevate your health journey! Resources *Note: Some of the resources below may be affiliate links, meaning Vicki Doe Fitness receives a commission (at no extra cost to you) if you use the link to make a purchase. Thank you for your support! Herbs and spices are the keys to delicious, flavorful, and sophisticated meals! FREE DOWNLOAD- Herbs and Spices Cheatsheet Let's get ECO-friendly. Try ECOLunchbox.com ECOlunchbox specializes in stainless steel bento boxes, artisan fair trade lunch bags, napkins, snack sacks, and other eco-friendly lunchware. They are a certified green business. ECOlunchbox is a consumer products company started by an eco mom in the San Francisco Bay Area. ECOLunchbox.com Go to our Resources page- For the most recommended tools, you need to succeed on your healthy living journey!! Listen and share our podcast show- “It's All About Health & Fitness-” Vicki Doe Fitness Subscribe to Apple Podcast Subscribe on Stitcher Or on any of the platforms that you listen to your podcast! Watch & Subscribe on YouTube! Catch our latest health & wellness videos on YouTube at Vicki Haywood Doe – Vicki Doe Fitness YouTube-Vicki Haywood Doe-Vicki Doe Fitness Join us to receive a health wellness message!
Today's guest is Cory Allen—a former police officer, longtime U.S. Secret Service Agent who spent years protecting Michelle Obama, author, dad, and advocate for LGBTQ+ family building.You may know Cory from his memoir, Breaking Free, where he shared his journey as a gay Secret Service Agent. Now he's written a children's book called Dada Takes a Trip, inspired by the very real emotions that come with leaving your child behind for a work trip—and helping kids understand that love doesn't disappear just because a parent is away.In this episode, Cory opens up about his path to parenthood through surrogacy, the losses and challenges he and his husband faced along the way, and what it's been like building their family. Cory and Ali also talk about fatherhood, vulnerability, the highs and lows of surrogacy, and why he believes more men should feel comfortable talking about their emotions.For more, go to https://www.coryallenbooks.com/IG: @authorcoryallenEPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe 3-book bundle is now just $49 (normally $79)!The latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.PHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.CARAWAYCaraway cookware is beautiful, first of all — like, actually gorgeous sitting on your stove — but it also makes cooking feel easier and less stressful.Visit carawayhome.com to take an additional 10% off your next purchase using code INFERTILEAF at checkout.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
In his weekly clinical update, Daniel Griffin and Vincent Racaniello opine on the recent executive order on the routine childhood vaccination schedule, the Ebola outbreak in the Congo and Uganda including the fast track trials for 2 vaccine candidates and antivirals, recent Hantavirus infections, use of quarantined "Hantavirus" patients for the governmental propaganda machine, use of ribavirin and other antivirals for Hantavirus associated cardiopulmonary disease, before Dr. Griffin deep dives into the measles outbreak, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, the measles outbreak in Bangladesh, as well as in a daycare center in Texas in 2025, how to access and pay for Paxlovid, FDA approval of a second COVID-19 antiviral drug, where to go for answers about long COVID-19, use of convalescent sera for COVID-19 treatment and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Childhood Vaccine Hesitancy (NEJM) One Year In: Public Views of a Changing Public Health Landscape (Harvard School of Public Health) Rotavirus Vaccine Coverage and Potential Barriers Among US Children Born From 2007 to 2024 (Pediatrics) Texas reports New World screwworm in 3-week-old calf (CIDRAP) USDA Confirms First Case of New World Screwworm in a Dog in Lea County, New Mexico, Fourth Case in Texas (USDA: Animal and Plant Health Inspection Service) Confirmed Detections of New World Screwworm (USDA: Animal and Plant Health Inspection Service) Mexico reports more human New World screwworm infections (CIDRAP) Frequency and persistence of post-acute symptoms after chikungunya, dengue, Zika and malaria in travellers: a prospective multi-centre study (Journal of Travel Medicine) Ebola dashboard (ebola.fyi) EBOLA:The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Modeled Scenario Projections for the Ebola Disease Outbreak Caused by Bundibugyo Virus, 2026 (CDC: MMWR) Assessment of Riskto the U.S. Population from the Ebola Disease Outbreak Caused by Bundibugyo Virus, 2026 (CDC: MMWR) How Ebola Disease Spreads (CDC: Ebola) Signs and Symptoms of Ebola Disease (CDC: Ebola) Hantavirusdashboard (Hantavirus.up) Hantavirus on board with Prof. VincentRacaniello (MicrobeTV) Some hantavirus-exposed cruise ship passengers return home to finish quarantine (CNN) Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons (LANCET: Infectious Diseases) First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib (Clinical Microbiology and Infection) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Anguished Parents, Crying Doctors: Life Amid Utah's Measles Outbreak (Wired) Characteristics of Patients Hospitalized with Measles During an Outbreak — West Texas, January–March 2025 (CDC:MMWR) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Respiratory Diseases (Yale School of Public Health) Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France (LANCET: Microbe) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national andregional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure (Businesswire) SARS-CoV-2 viral shedding and vaccination‑modified effects of oral antivirals in older COVID-19 patients: a retrospective cohort study in Hong Kong (International Journal of Infectious Diseases) SARS-CoV-2 vaccination and attenuation of breakthrough infection severity: A systematic global review and meta-analysis (CID) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial (CID) Reaching out to US house representative Letters read on TWiV 1330 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.
RURAL ROUTE WITH TRENT LOOS: THE TRUTH ABOUT DMSO — NATURAL HEALING YOU'VE NEVER HEARD OF Rebecca Cuningham of RedFlyerMedia.com joins Trent Loos to uncover the real story behind DMSO — dimethyl sulfoxide — a powerful natural compound the FDA tried to bury in the 1970s. Here's the twist: if you use DMSO correctly it will heal your bodies cells.
The U.S. administration is keen to sign up more companies to drug pricing deals, and mandatory rules are on the way. But how will the midterm elections affect these and other healthcare policy issues? At RBC's Global Healthcare Conference, Hunter Hammond and Will Humphrey of Capstone's healthcare group offered insights on the direction of policy for the rest of the year and beyond. Key PointsMandatory Most Favored Nation pricing rules are likely to be contested in court.The FDA's initiatives to speed drug development are signals of its modernization intent.The U.S. is more likely to use incentives than sanctions to address mass in-licensing of Chinese innovation.The current program to extend access to GLP-1s could be a template for future breakthrough drugs.Democrat gains in the midterm elections would likely limit further hospital cuts.Introductions [00:08]Host Joe Coletti introduces highlights from the U.S. Healthcare Policy Panel at RBC's Global Healthcare Conference, featuring Hunter Hammond and Will Humphrey of Capstone's Healthcare Group. Midterm campaigning [00:40]In the run-up to the midterms, the U.S. administration will aim to focus on messaging about popular policies, such as cutting waste and fraud in Medicare and Medicaid.FDA changes [01:41]After turmoil in the FDA, new leadership is designed to promote stability. Recent moves to speed drug approvals are likely to continue and offer an important signal about FDA modernization. Chinese innovation [04:31]The administration may be uncomfortable with U.S. in-licensing of Chinese technologies, but it is more likely to respond with incentives than any attempt to block the practice.Drug pricing [06:17]Most Favored Nation mandatory pricing models have yet to be finalized and are likely to be challenged in court. Democrats will not support codification of MFN.Democrat priorities [08:08]Democratic gains in the midterms would have the effect of protecting hospitals from further cuts. Reform of 340B is unlikely, however.
Julia Cartwright examines what Ozempic actually is — a diabetes medication, not an FDA-approved weight-loss drug — and explores the real experiences behind the headlines. We discuss effectiveness ranges, common side effects like nausea and gastroparesis, weight regain after stopping, and why semaglutide works best as one tool in comprehensive care. Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI
Comedians H. Foley & Kevin Ryan join Big Jay Oakerson, Luis J. Gomez, and Ari Shaffir for the third round of the 2026 Springtern Olympics! The guys discuss the influencer couple who recently announced the terminate their pregnancy after a down syndrome diagnosis. Plus, Foley and Kev analyze the interns and place them on a sliding scale of garbage, then the bottom two battle for their spot in a syrup chugging race. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 06/09/26Support our sponsors!Visit BodyBrainCoffee.com and use code LOS20 for a limited time to get 20% off your order! #BodyBrainPodSupport the show & get 30% off SITEWIDE for Father's Day at https://www.sheathunderwear.com #SheathPodSupport the show & get 20% off your Ruiget order with code SKANKS at https://www.rugiet.com/skanks DISCLAIMER: Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com.New customers get 40% off with code SKANKS at http://GLD.com #GLDpodDon't sleep on @ultrapouches. New customers get 15% off with code LEGION at http://takeultra.com #UltraPouches---------------Skankfest X New Orleans badges available at www.skankfest.com!---------------
Semaglutide Slows Biological Aging A randomized, placebo-controlled study published in Nature Communications found semaglutide slowed biological aging markers by nine percent on the DunedinPACE epigenetic clock in adults living with HIV-associated metabolic disease, with simultaneous improvements across inflammation, heart, kidney, liver, and brain markers. Host Dave Asprey breaks down why this isn't a weight loss story. It's a metabolic inflammation story. He explains why the GLP-1 mechanism hitting insulin signaling, oxidative stress, and inflammatory pathways simultaneously is the real finding, and makes the case that your metabolic markers and your aging markers are the same numbers. Sources: https://www.medicalnewstoday.com/articles/glp-1-drugs-ozempic-wegovy-may-slow-biological-aging https://www.nature.com/articles/s41467-026-72861-3 https://today.ucsd.edu/story/study-popular-glp-1-drug-may-slow-down-biological-aging FDA Approves First New Sunscreen Ingredient in 20 Years The FDA approved bemotrizinol as a permitted OTC sunscreen active ingredient, the first new approval in roughly two decades, clearing it for adults and children six months and older with broad UVA and UVB coverage and low skin absorption. Host Dave Asprey explains why twenty years of regulatory lag left American consumers with inferior chemistry while Europe moved on, why he's watching independent absorption data before updating his own stack, and why consistency of use matters more than perfect formulation when sun protection remains one of the most evidence-backed longevity interventions available. Sources: https://www.fda.gov/news-events/fda-newsroom/press-announcements/fda-expands-sunscreen-options-first-time-20-years https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm?event=OrderDetail&orderid=OTC000039 https://www.usatoday.com/story/news/health/2026/06/09/new-sunscreen-ingredient-bemotrizinol/90477659007/ Deoxyribose Gel Matches Minoxidil in Hair Regrowth Study Researchers testing a topical gel made from deoxyribose, the sugar backbone of DNA, saw roughly 80 to 90 percent hair regrowth in a mouse model of male-pattern baldness, matching minoxidil results and showing new follicle formation and increased blood vessel activity in treated areas. Host Dave Asprey breaks down why mouse hair regrowth studies have a long history of failing to translate to humans, what a plausible circulation-based mechanism would actually need to show in human trial data before it's worth acting on, and why the molecule itself is interesting enough to keep watching. Sources: https://www.reddit.com/r/Biohackers/comments/1tyt87w/researchers_found_that_a_gel_made_from/ https://www.sciencealert.com/surprise-hair-loss-breakthrough-a-dna-sugar-gel-sparks-robust-regrowth Caffeinated Chewing Gum and Exercise Performance A systematic review and meta-analysis of 21 studies found caffeinated chewing gum produces a small but real ergogenic effect for muscular strength and countermovement jump height, with buccal absorption delivering caffeine faster than capsules or drinks in a five to twenty-five minute pre-training window. Host Dave Asprey breaks down why delivery mechanism is an underrated variable in caffeine optimization, why timing matters as much as dose, and why a modest but measurable edge on a cheap and accessible tool is exactly the kind of practical biohack worth understanding. Sources: https://pubmed.ncbi.nlm.nih.gov/42228847/ https://doi.org/10.1519/JSC.0000000000005530 https://www.reddit.com/r/Biohackers/comments/1u0acgc/fastacting_caffeine_does_caffeinated_chewing_gum/ Vitamin A Overdoses Surge Nearly 40 Percent Medical News Today reported a 38.7 percent spike in vitamin A overdoses in early 2025, driven by online misinformation claiming high-dose vitamin A treats or prevents measles, a claim with no clinical support and real toxicity risk from fat-soluble accumulation in the liver. Host Dave Asprey explains the actual hepatotoxicity and bone demineralization risks of preformed retinol excess, draws the critical distinction between preformed retinol and beta-carotene that got lost in the misinformation cycle, and makes the case that mechanism is not a dosing protocol and confusing the two is how people get hurt. Sources: https://www.medicalnewstoday.com/amp/articles/vitamin-a-overdoses-rose-by-38-7-2025-how-to-get-right-amount World Cup 2026 and Mass Gathering Health Risk With the 2026 FIFA World Cup underway, public health researchers are flagging dense international crowds, high-volume travel, and shared indoor and outdoor spaces as an elevated transmission environment for respiratory illness. Host Dave Asprey reframes the conversation away from germ exposure and toward immune terrain, explains why your resilience going into a high-contact environment is a variable you actually control, and lays out the pre-exposure preparation window that matters most for anyone traveling or attending large events this summer. Sources: https://www.healthline.com/health-news/2026-fifa-world-cup-health-risks-protect-yourself This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on GLP-1 aging biology, sunscreen chemistry and regulatory science, emerging hair regrowth research, caffeine delivery optimization, supplement toxicity risk, and immune terrain preparation for mass gathering events. Host Dave Asprey connects randomized clinical data, epigenetic clock research, consumer health regulation, and real-world optimization protocols into actionable frameworks for extending healthspan, sharpening performance, and staying ahead of the science. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: semaglutide biological aging, GLP-1 epigenetic clock, DunedinPACE aging marker, PCGrimAge mortality risk, bemotrizinol FDA approval, new sunscreen ingredient 2026, UVA UVB broad spectrum sunscreen, deoxyribose hair gel, minoxidil alternative hair regrowth, caffeinated chewing gum performance, buccal caffeine absorption, pre-workout caffeine timing, vitamin A overdose toxicity, preformed retinol hypervitaminosis, fat-soluble vitamin accumulation, World Cup 2026 health risk, immune terrain optimization, mass gathering respiratory illness, biohacking news 2026, longevity research, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Viome | Check it out at viome.com and use code 10DAVE for 10% off. It's time to stop guessing and start knowing your body. - Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:41 – Story 1: Ozempic Slows Aging Clocks 01:53 – Story 2: New Sunscreen Approved 03:12 – Story 3: DNA Sugar & Hair Regrowth 04:38 – Story 4: Caffeine Gum & Performance 06:13 – Story 5: Vitamin A Overdose Spike 07:59 – Story 6: World Cup & Immune Prep 09:34 – Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Until this week, the United States hadn't approved a new sunscreen ingredient in over 20 years. That changed Tuesday, when the FDA approved a new chemical for U.S. sunscreens. It's called bemotrizinol, and NPR science correspondent Maria Godoy joins us to tell us all about it — including the soonest it's expected to hit shelves.Interested in more science news? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy
Amye is joined by Becca to “investigate” Steven McBee Senior. As you may remember, he pleaded guilty to fraud last year and has recently been sentenced. But what exactly did Steven McBee Senior do to land himself in jail for 24 months? We took to the internet to find out.Join us next week for our full coverage of The McBee Dynasty season 3!GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.
A flood destroyed the factory, the FDA shut them down, and the company had almost no cash and then something remarkable happened. Ramon Vela sits down with Alex Whitmore, Founder & CEO of Taza Chocolate, for a deeply human conversation about twenty-plus years of stone-ground, mission-driven chocolate making in Somerville, Massachusetts. From a transformative trip to Oaxaca to pioneering direct trade relationships with cocoa farmers in Haiti and the Dominican Republic, Alex's story is one of the most compelling in the specialty food world. * The flood that almost ended everything. Just a few years into building Taza, a freak thunderstorm flooded the factory, destroyed inventory, and triggered an FDA shutdown. What happened next surprised even Alex: suppliers, customers, landlord, and community all showed up. That moment taught him that business is deeply human at its core. * A trip to Oaxaca that changed everything. The name Taza comes from "taza de chocolate," a traditional Mexican drinking chocolate. After visiting stone mills in southern Mexico in his twenties, Alex came home and built the only company in America making chocolate on traditional Mexicano stone mills — and that founding commitment still defines every bar made today. * Direct trade before it was a trend. Taza built relationships directly with cocoa farmers, paying above fair trade prices and publishing an annual transparency report. When the global cocoa crisis hit and prices spiked, those long-standing farmer relationships became a genuine competitive and operational lifeline. * Twenty years of staying independent. Taza raised only $120,000 at the start and never chased outside capital. Alex walks through what two decades of bootstrapping in an intensely competitive specialty food category actually teaches you about patience, resilience, and staying true to your craft. * Start with the Wicked Dark. Taza's number one seller is a 95% dark chocolate bar made with cocoa beans from the Dominican Republic and Haiti. Alex also points new fans to the Mexican Style Chocolate Discs, the product that best captures who Taza has always been. Join us in listening to this episode for a rich and genuinely moving conversation about craft, community, and what it means to build a brand with deep roots and unshakeable values over two decades. Whether you are a chocolate lover, a founder, or someone who just needs a reminder of why the mission matters, this one will stay with you. Visit: https://www.tazachocolate.com/ If you enjoyed this episode, please leave The Story of a Brand Show a rating and review. Plus, don't forget to follow us on Apple and Spotify. Your support helps us bring you more content like this! * Today's Sponsors: Saral - The Influencer OS: https://www.getsaral.com/demo SARAL is the all-in-one influencer platform that finds brand-aligned creators, automates outreach, and manages everything in one place. Request a live demo today. Let the SARAL team know you're a The Story of a Brand Show podcast listener to get an extended free trial! Visit the link above.
Send us Fan MailYesenia Avellaneda is an engineering leader whose career sits at the intersection of innovation, operations, and impact. Currently a Senior Project Engineer within Global Operations at Abbott, she has built a reputation for turning complex ideas into scalable, high-performing manufacturing systems. From leading New Product Introduction (NPI) efforts to executing international production transfers and launching entirely new facilities, Yesenia thrives where strategy meets execution. Her work has had measurable impact. She has led capital projects exceeding $5 million, driven production efficiency improvements, and implemented Lean manufacturing and Six Sigma methodologies to enhance quality and throughput. In one role, she helped boost line productivity by 200%, all while overseeing teams of 60+ personnel and ensuring compliance with rigorous FDA and regulatory standards . Her ability to align cross-functional teams—from product development to operations—has made her a key driver of successful product launches and operational excellence. Yesenia's academic foundation reflects her human-centered approach to engineering. She earned her bachelor's degree in Human Physiology from the University of Oregon and later completed a master's in Biomedical Engineering from the University of Portland. This unique combination allows her to bridge the gap between clinical needs and engineering solutions—an essential skill in the medical device industry. Beyond her technical and leadership accomplishments, Yesenia is deeply committed to giving back. As Regional Vice President for SHPE Region 6 and a longtime advocate for underrepresented communities in STEM, she actively works to create inclusive pathways for future engineers. She's also an experienced speaker, sharing insights on leadership, career growth, and navigating STEM as a first-generation professional. In this conversation, Yesenia brings a rare perspective—one that combines hands-on engineering, large-scale operational leadership, and a mission-driven approach to making a broader impact in both industry and community. LINKS: Yesenia Avellaneda LinkedIn: https://www.linkedin.com/in/yesenia-avellaneda/ https://shpe.org/ Aaron Moncur, host Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment like cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us at www.teampipeline.usWatch the show on YouTube: www.youtube.com/@TeamPipelineus
In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40
Jordan Sather and Nate Prince tackle a rumor mill moment first: Robert Malone claims RFK Jr. is set to resign as HHS Secretary in July, and HHS immediately fires back calling it fake news. Jordan, who has tracked Malone's track record before, is skeptical but keeping receipts. Then things get heavy fast. Senator Ron Johnson calls the COVID vaccine cover up a scandal bigger than Watergate, and a powerful clip from a Children's Health Defense event captures the moment people realized the system was lying to them. On a lighter note, RFK and Ben Greenfield talk biohacking basics: sunlight, breathwork, and why you do not need fifty bottles of skincare products. The FDA approves a new sunscreen ingredient after 25 years, and Jordan explains why most drugstore sunscreens are trash. Plus, ivermectin shows real promise in cancer treatment, screwworm creeps back into Texas, and a new study links ultra processed food to a 60 percent higher dementia risk. Coke and Hershey are apparently on board with MAHA now. Sure.
This CEO Is Advancing Neuroscience, Reducing Pain, & Treating Epilepsy – Meet Dave Rosa, CEO, NeuroOne Medical Technologies $NMTCGuest: Dave Rosa, CEO, NeuroOne Medical Technologies $NMTCDave's BioDave Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa's background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.Mr. Rosa currently serves as the President and CEO of NeuroOne (Nasdaq: NMTC), a medical technology company that develops high-definition, minimally invasive diagnostic and therapeutic devices based on its unique thin film electrode technology. NeuroOne, Nasdaq: NMTCWebsitehttps://nmtc1.comCompany Bio NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo(R) Cortical Electrodes, Evo(R) sEEG Electrodes, OneRF(R) Ablation System (for brain), and OneRF(R) Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery and spinal cord stimulation programs.
"The average marketplace deductible grew by about $1,000 per person in 2026. Premium payments increased by an average of 58%... We might be seeing the death throes of the fully insured market."Welcome back to Last Month in Healthcare! This month, Spencer, Nathaniel, and special guest Jonathan Lopez break down the most impactful healthcare headlines and regulatory shifts from May 2026.The episode kicks off with a discussion on the sudden resignation of FDA Commissioner Dr. Marty Makary following reported clashes with the food, tobacco, and pharmaceutical industries. From there, the guys dive into the shocking 58% premium hikes and 37% deductible increases hitting the ACA marketplace as carriers like Cigna exit the space.Finally, Spencer and Jonathan play a World Cup-themed game guessing the cost of medical procedures across different North American cities and answer a listener question about Cost Plus Drugs and the rise of direct-to-consumer pharmacy models.If you'd like your question answered on next month's episode, call/text 469-213-6381 and leave us a voicemail/text.Thank you to our sponsor, Walk On Clinic. This month, we shared a tragic reminder to our listeners on the critical importance of early cancer detection and proactive primary care. To hear Chris's brother-in-law's music, tune in here: https://open.spotify.com/artist/1SKw4DO9FNLjcZDb5Q81q4?si=Dwpuz2wOTRawhMDfR5NIsAEpisode Chapters:(00:00:00) Intro: The Importance of Early Detection & Walk-On Clinic(00:02:30) Dr. Marty Makary Resigns as FDA Commissioner(00:04:37) ACA Marketplace Premiums Skyrocket by 58%(00:07:51) HR 8163: Stopping the Squeeze on Physician Reimbursements(00:12:34) Harvard Study: AI Outperforms Doctors in ER Triage(00:14:53) The FDA's Push for Hospital-at-Home Devices(00:17:18) Game: Guess the Procedure Cost (World Cup Edition)(00:21:22) Ask Spencer Anything: Cost Plus Drugs & D2C Pharmacies
Comprehensive coverage of the day's news with a focus on war and peace; social, environmental and economic justice. Iran, U.S. reach agreed text on cease-fire deal, mediator says. House war powers vote symbolic but significant, legal scholars say. Judge extends freeze on Trump's anti-weaponization fund, demands sworn statements that it's dead. Veterans Affairs subcommittee hears complaints about VA appointment delays. Trump's name poised to be removed from Kennedy Center after court denies last-minute move to keep it. FDA approves emergency over-the-counter screwworm treatment for pets. The post Iran, U.S. reach agreed text on cease-fire deal, mediator says – June 12, 2026 appeared first on KPFA.
Professor of ophthalmology Daniel Palanker is a physicist who has combined his skills in optics and electronics to create PRIMA – the Photovoltaic Retinal Implant. Inserted beneath the retina, it restores vision to patients blinded by retinal degeneration, allowing them to read and write – and with the next-generation software, to recognize faces. PRIMA's photovoltaic pixels act like tiny solar panels, converting light into electricity to stimulate the remaining retinal neurons. Better yet, the growing field of brain-computer interfaces may have implications beyond ophthalmology. “Unlike medicine, where the road ends with curing a disease or restoring lost function, the prospects for brain-machine interfaces may be infinite,” Palanker tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Daniel Palanker Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Daniel Palanker, a professor of ophthalmology and electrical engineering at Stanford University. (00:03:17) Path into Ophthalmology How Palanker's background in physics and optics led him to vision research. (00:04:33) How Vision Works A primer on the eye, retina, photoreceptors, and the neural code of sight. (00:08:50) Retinal Degeneration How diseases like macular degeneration and inherited retinal disorders damage vision. (00:13:18) The PRIMA Implant How a photovoltaic retinal implant converts light into electrical stimulation. (00:15:05) Augmented Reality Glasses How camera-equipped glasses amplify and project images to power the implant. (00:17:42) From Reading to Face Recognition Why grayscale vision is the next step toward recognizing faces. (00:20:18) Implanting the Device How the wireless chip is placed under the retina and powered by light. (00:21:45) Replaceable Vision Technology How future generations of implants could be swapped in for higher resolution. (00:22:28) Limits of Resolution Why geometry and proximity to neurons determine how small pixels can get. (00:24:00) Moving to 3D Electrodes How pillar-shaped electrodes help neurons move closer to the implant. (00:26:28) Clinical Path Forward The status of European trials, FDA discussions, and future patient access. (00:28:10) Safety and Real-World Use What trials reveal about surgical risks, durability, and patients using implants at home. (00:30:11) Future In a Minute Rapid-fire Q&A: neural coding, brain-machine interfaces, and restoring vision. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
On episode 109 of Astonishing Healthcare, host Justin Venneri explores pharmacogenomics (PGx) with a trio of experts: Caitlin Munro, PharmD (Clinical Partnerships Lead, Judi Health); Haleh Campbell, PharmD (Clinical Programs Administration Manager, Judi Health); and Houda Hachad, PharmD (Vice President of Clinical Operations, Aranscia). Together, they break down what PGx is, why now is the right moment for broader adoption, and how genetics can shape the way each of us processes and responds to medications.The conversation moves from the basics to the practical: where the evidence is strongest, which patients stand to benefit most, and what it takes to apply PGx in a way that's clinically responsible and genuinely useful for patients and providers. They also dig into findings from a study the Judi Health team recently presented at the Pharmacy Quality Alliance (PQA) annual meeting and explain why pharmacist support and clinical decision support, not just a lab report, make all the difference.Key TakeawaysPGx adds a piece to the puzzle; it's not a silver bullet. Pharmacogenomics looks at how inherited genetic differences affect the way a person processes or responds to medications. It narrows uncertainty and supports clinical judgment, but it doesn't replace it.Several forces are converging to make this the right moment. Testing costs have dropped, evidence-based guidelines from expert consortia are now widely adopted, and hundreds of FDA labels include pharmacogenomic information.The strongest use cases involve complexity and risk. Patients on multiple medications, those starting new therapies, and people who've had treatment failures or unexpected side effects often benefit most, especially across common drug classes like antidepressants, cardiovascular medications, and pain therapies.Human support drives engagement and trust. Rx Helix data showed that testing adoption was significantly higher among members who received clinician-led, pre-test telephone outreach.The future is proactive. With unified claims processing that combines pharmacy and medical data, leaders see a path toward PGx-enabled medication management, identifying patients before therapy begins to optimize treatment earlier in their journey.Related ContentHealth Benefits 101: The Importance of Clinical ProgramsAH073 - How Low Cost Alternative Programs Can & Should Work, with Jackie Lolos, PharmD, and Haleh Campbell, PharmDReplay – The Bridge to Better Healthcare: Uniting Medical and Pharmacy Services on One Platform to Achieve Value-Based CareAH060 - A New Approach to Colorectal Cancer (CRC) Screening, with GeneoscopyFor more information about this episode and its transcript, please visit Judi Health Insights.
A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia treatment Hympavzi gains expanded indication; and the FDA adds a warning label for kidney injury to an over-the-counter weight loss aid.
Dr. Amel Havkic, founder and Managing Director of EvoMed Consulting and a practicing physician, unpacks why so many amazing medtech solutions never reach the patient bedside, along with advice on how to change that. Driven by frustration from frontline care, Amel built EvoMed to guide companies from development through real-world clinical adoption, and shares how his MBA research became the StarMap framework: seven success factors spanning workflow alignment, implementation friction, ecosystem fit, quality of care, and economic viability. He explains why staying in clinical practice matters as medical knowledge rapidly evolves, offers a real example of digitalization increasing clinician burden, and discusses AI as “augmented intelligence” that supports—not replaces—human decision-making. Guest links: https://evomed-consulting.eu/ | https://www.linkedin.com/in/a-havkic/ | https://www.instagram.com/evomed_consulting?igsh=aTlyaGVmeXYybGt3 Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com. PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical EPISODE TRANSCRIPT Episode 082 - Amel Havkic [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of the Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to welcome my guest, Amel Havkic. Amel is founder and MD of EvoMed Consulting, Department Head for Weaning and Home Ventilation. Dr. Amel is also a consulting medical director for many companies, apart from being an educator, mentor, author, and currently working physician. All right. Well thank you so much for being here. Welcome to the show. I'm delighted to talk with you today. [00:01:23] Amel Havkic: Thank you so much. It's a pleasure being here, and thank you for having me. [00:01:27] Lindsey Dinneen: Of course. I'd love if you wouldn't mind starting off by sharing just a little bit about yourself, your background, and what led you to medtech. [00:01:37] Amel Havkic: Okay, so my name is Amel Havkic. I am still a practicing physician. But on top of that, I'm a advisor in medtech. I am in medtech since something like six, seven years, and it actually came from the frustration that I had in everyday work on the patient bedside. I was already consulting some medtech companies on specific topics. And I've seen this huge gap between amazing medtech solutions which, however, for whatever reason, never made it to the bedside. So I ended up, I ended up fund founding EvoMed Consulting consultancy, which helps medtech companies with clinical adoption, pretty much helps them guide from the development all the way to the patient bedside. The solutions really getting adopted, really having an impact. We've had quite some success with this. We've been named best Market Access Consultancy in '25 in medtech. I personally also celebrated recently award for Best Rising Star of the industry. And yeah, all of this came from the idea that I wanted to see a world where no patient is left behind and independent of geography or economy or economic status. Every patient gets the best care imaginable. And yeah, what better way to deliver that than medtech, right? [00:03:05] Lindsey Dinneen: Yes, that was the perfect plug for medtech right there. That was excellent. So first of all, congratulations on all of your success and these recent achievements. That is really exciting and incredible and I, I know that your motivation goes obviously so much deeper than that, but I love the fact that you're getting recognized and it's, it's nice to have those moments of affirmation, so. [00:03:31] Amel Havkic: Yes, it is. I said it on the interview, which I got after the, after the award. It's not even about the award itself. It is actually about what I stand for and that is the human side of medtech. I mean, it is technology, but we're still doing it for humans. And as a doctor getting recognized and not as a founder, it is something it, it is a signal. So that's the, I think that's the positive, the good part about it, and that's what makes me proud. [00:04:03] Lindsey Dinneen: Yeah. Yeah, absolutely. So did you always have an interest in medicine? Did you always think you were gonna go this route? [00:04:11] Amel Havkic: In medicine, yes. I think as far as I can remember, thinking I wanted to be, I wanted to be a doctor. I was trying to cater to wounded animals as a, as a kid with, I don't know, four or five, six years old. Then I went to med-- no, before I went to med school, I was doing basically nursing school. I grew up in Bosnia, in Sigovina There it's after eighth, eighth grade, you decide what you actually want to do. So I decided I wanted to go into medicine and at that time, Dr. House came out and or house MD in, in the English, English terminology. And I was a huge fan. So that was pretty much my, my route was set from that. I was al also always tech savvy, so if I wouldn't have done medicine, I would've probably done IT. And at one point it kind of merged. [00:05:09] Lindsey Dinneen: Wow. Okay. All right. So Dr. House, I can totally understand why that became an, an inspiration. Do you have any examples that you could share that are like, is, is the medical world ever as wild as some of those stories on Dr. House? [00:05:27] Amel Havkic: Oh yes. Oh yes. It is specifically. So besides working in the hospital, I work in a private practice, and funny enough that private practice is focused on difficult to diagnose and rare diseases of, obviously for, for that reason. I was also working in a hospital department, which was working with with or in discovering rare diseases specifically when it comes to, to respiratory diseases. So, yeah, it is like that. I can share a story of one patient, which came to me because she had thoracic pain every now and then. And it was reoccurring, came again and again. I did an ultrasound, and so she was at a cardiologist, she couldn't find anything. The, the whole thing. And it, I did an ultrasound of the chest and I found a, a little a little mass, which is not supposed to be there. So I sent her to a CT. Funny enough, the CT came back negative because it was so small that you couldn't see it on a ct. However, when you know exactly where to look, you could still like see outlines of it. And then in the, in the discussion came out that she had an endometriosis at one point. So, we said, "Okay, this might be somehow connected." We took a tissue sample, so in the end it was indeed an endometriosis, which got discovered after 20 plus years of or, or 10 years of, chest pain every now and then. So, it's just one of the examples of the, of the, so yeah, it's Dr. House specifically is quite realistic. [00:06:57] Lindsey Dinneen: Oh my goodness. That is wild. I, wow. Okay. That is, that is really cool. So, so do you also have these these moments, I could just imagine you just feel like you've solved a mystery and you can help this patient and you know exactly how, is that just like the best feeling? [00:07:13] Amel Havkic: For, for me it is, for me, it is, I always have to describe or, or tell to my assistants in a or, or not assistants, my residents. Please don't misunderstand me. I get excited by this, not because I want the patient to be sick, but because first of all, we find a way to help after so many people could not. And yeah, just for the pure love of the game, so to say. [00:07:37] Lindsey Dinneen: That's amazing. Okay, so, well, I feel like we can go off on many tangents, but I'll, I'll try to, I'll try to stay focused because I, but I love that. I love that. So you're a practicing physician and you're, you're seeing these instances of medical technology that I imagined isn't getting adopted in the way that you know it should, that would have clients or patient impact. So you're, you're seeing this for a while. So did that lead to direct opportunities to consult for some of these companies that needed a physician's perspective or how did, how did that go from, "Hey, I, I, gosh, I'm seeing this gap" to, "Okay, I know where to go from here." [00:08:19] Amel Havkic: So, it exactly like that. So I was brought into a medtech company to consult them as a clinical medical expert on, at that point, risks associated to their solution. Of course it makes sense to have someone who is still in the trenches, so to say, because the logic behind certain workflows in hospitals or in healthcare environment is not the same logic that it guy would have when talking workflows similar. So that's how it started. And then a pattern started emerging. When I did my MBA thesis, I basically took, took these two, these two, that, that gap that I saw and made it a topic of my MBA thesis. I was looking specifically on success factors in healthcare and what makes a solution gets adopted or delivery system healthcare path, what makes it get adopted in the real world and what does not. And what emerged was basically knowledge graph constellation, so to say, of seven success factors. And that constellation also showed how they're connected with each other, so, and how they interact how they impact one another. So I put that to the, to the to the test, the findings, running multiple times the most profitable hospital unit in basically every hospital I went to, starting my private practice, which got profitable from day one. Consulting clients on the same on the same, framework who were able to triple their, their revenue from 30 to 90 million. And so on, so forth. And ultimately then just about half a year ago, I made the framework public, and that's the StarMap framework which is the moment when everything kicked off. So everything I I said after all the awards and all the recognition came after I shared what I've been holding back up until that point. [00:10:25] Lindsey Dinneen: Okay. Alright. Wow. All right. Can you share a little bit about this framework and what makes it so unique and impactful? [00:10:34] Amel Havkic: So what the eye recognized is that it works because it's basically backwards engineered. I had the benefit of hindsight and had the benefit of seeing the solutions, which really made it to, to the patient bedside. So this is a challenge that many medtech companies, specifically the medtech startups face. You know, they come actually from the other side trying to pick one of the hundreds, if not thousands of ways to to, to navigate, to come to that one point where they want to be. For me, it was exactly the other way around. I was already where they want to be and was able to backwards and engineer those factors. And it is, when you think about it or when you read through it, it's almost common sense. Factors like specialization, cooperation and ecosystem fit, workflow alignment, predictability of services. But also implementation, friction digitalization, quality of care, and specifically economic viability. So pretty much a 360 view on the, the, on the solution because when you, when you come to think of it, for something to get adopted in the clinic, there is a lot of different stakeholders involved. So it's not just the doctors, it's not just the clinics, it's the insurance companies, it's the the procurement, IT. Does this at all integrate into my ecosystem and so on so forth as a whole bunch of stakeholders and questions that need to be answered. And the StarMap is the first framework, which basically has a, a structured way of looking through all of these. [00:12:16] Lindsey Dinneen: Okay. Yeah. So this is, this is a framework that you have, I imagine, developed and refined over time as you've been consulting. So when you first started consulting, what are some of maybe the lessons that you learned in terms of being able to really help these companies succeed? [00:12:35] Amel Havkic: This is a bit more of a personal one because, I founded a consulting company. So my thought I had, I have no clue about marketing. I have no clue about those things. I'm a doctor, right? So, I imagined that what I should be is a consultant, right? After all, I'm consulting. It turns out that the, the biggest impact I could make, in fact as a doctor, because in the end, that's what I am, it's what is most natural to me, and that is what is bringing most impact to the clients. And then there's one specific thing which I have, which many other consultants in healthcare, also good consultants, don't have. And it is the fact that I'm still practicing. Fact is that today medical knowledge doubles every 73 days. In theory, that means if you are out of the healthcare delivery for 73 days, your knowledge is almost obsolete. It was way less, it was a few years when I studied. And now it's, it's became so exponentially big. What that means is that if you would take a doctor, and make him a consultant, drag him out of the hospital, he would be an expert for 73 days, and that's where it would stop. And this is the, this is pretty much the, the mindset that I adopted and everyone consulting in the EvoMed is still a practicing, practicing healthcare practitioner. So yeah, that's what makes EvoMed specifically different and that's how I saw the world before and how I see it now. [00:14:09] Lindsey Dinneen: That's incredible. Okay. Yeah. And, and it makes so much sense that if you're practicing then you're, you're needing to keep up on all that. But just on a very practical level, how do you stay on top of so much new information coming out so regularly? I mean, it's not like, you know, you don't have three major career things going on right now. [00:14:33] Amel Havkic: Yeah, I think by now it's a flywheel, and luckily I, I am the very, in the, in the very lucky position that my, that my hospital knows and accepts what I'm doing outside of the hospital and also supports this. So, I get updated regularly through through people talking to me, reaching out to me, showing their solutions, asking for my opinion. And on the other side, so, so that's, that's what keeps me updated on a regular. And on the other side, I still I still see the challenges that you would have in a hospital implementing those solutions. So, recently the one specific thing happened, just as an example. We, I, I was involved or I'm involved in a digitalization pro project of an ICU and of operating room. For that they have now from, from paper, from from paper notes, they're switching to digital. Problem is the paper notes they could fill out within five minutes while the digital have all kinds of mandatory fields. And, and it's kind and, and the time it takes a physician to fill out those, those digital forms is six times... [00:15:47] Lindsey Dinneen: Hmm. [00:15:47] Amel Havkic: ...More, so it's 30 minutes roughly if you're fast. So although you would think that something which gets digitalized is automatically better, this specific thing proves that just because someone thought, okay, I need this information, it need, this needs to be mandatory. But because the system maybe doesn't communicate with other parts of the system, legacy systems, legacy data from somewhere, it makes the job of the doctor living hell. So you, you can imagine how it is when you have like one person doing, I don't know, 40, 50, 60 pre-medication a day, and then from like five to 10 minutes pre-medication, it goes to 30 minutes, 60 minutes. That's, that's a problem. [00:16:31] Lindsey Dinneen: Yeah. So yeah, that is, that's, that is so interesting. It's, it's kind of, I suppose that goes into a lot of innovation. There are sometimes, you know, the things that we think, "Oh, well, this is, this is progress" and, and it might be, but just because you can doesn't mean it's always perhaps the most efficient or we should at least stress test it and decide, you know, how to make it the best it can be. So, all right, what are some, what are some trends and innovations that you're seeing that you're really excited about in terms of the future of medical care? [00:17:08] Amel Havkic: Well, obviously AI is a, is a great trend. I am really hoping that it'll take the, the proper route. I am, I've, I've been saying this a lot and I will repeat it again. When I say AI in healthcare context, I don't like AI as artificial intelligence, but as augmented intelligence, because what it's supposed to do, it's supposed to support our natural decision making process. And a decision in a high stakes environment like healthcare still needs to be in the hands of humans because there's much more to it than just a simple yes or no, or a statistic, or it's most probable that and that is a trend. So, so that is a technology which has huge potential. But so far, I must say oftentimes I see it implemented in the wrong way. It's trying to automate certain things either not good enough, or at certain points, or in such a way that it's not a livable in daily life or meets resistance. Specifically in healthcare, it's a very inert system because innovation in healthcare is perhaps dangerous is, it introduces new risks. That's why healthcare evolved to be a very inert system and to resist changes unless those changes are definitely proven to be better than what we have right now. So as an example, we had IBM Watson Oncology, huge player, huge possibilities. But somehow the, the way that Watson Oncology did things was not the way that clinicians wanted to use it. So in the end, they ended up selling it off. And that is just one example of many, many. So what I would really like to see for the future is AI is augmented intelligence, which really is positioned at the right places in a workflow of healthcare practitioners and help support their decisions rather than trying to automize or making them obsolete. [00:19:24] Lindsey Dinneen: Yeah, that makes a lot of sense. And it's, it's something that of course we hear a lot about, you know, and, and a lot of times I think that what I've been hearing, exactly like you said is, you know, if it can help, if it can help minimize some workflows or make something more, a process more efficient or those kinds of things, that is great help. But I don't think anyone wants AI to replace the expertise and the hands on learning that you do. And, and you obviously every 73 days, like you said, you're constantly building up your, your knowledge bank. And literally having been in the, in the medical setting for so long, you've, you've gotten to see this play out in real life and AI can't do that. So yeah, that's really interesting. [00:20:12] Amel Havkic: True. What, what it can do however, is just like every other job, healthcare also has a bell curve. So you have 5% or a percentage of the practitioners who are massive under performers, a percentage which are massive over performers, and then there's an average in the middle. And what, what AI can do is it can help even out the bell curve and move it as far to the expertise side as possible. There's also other repetitive tasks which, which can be taken over. So I do see potential in the, I do see a lot of potential in that technology specifically. But just as another example in my private practice, I have a. I have a AI scribe. It is specific for medtech. It's not something that I misuse, foreseeable misuse, for all the regulatory people. But it is an AI scribe. Still, most of my colleagues are not using it because they say, "Okay, this does not fit our needs. And it is not that specific scribe that we use." You cannot tweak the way how it gives you the output. It's preset. You can optimize certain things, but you cannot, for instance, train on your on the way you like your letters to look, for example. Then there's errors. So although you think, "Okay, you save a lot of time typing," right? You add at another point another a few work steps with the solution and ending up being shelved again because it's not really helping. Although from the, from the first glance, on the first glance, you would think, "Okay, this is revolutionary." [00:21:55] Lindsey Dinneen: Hmm. Yeah. Yeah. Okay that. Yeah. So it's gonna be interesting to see how it evolves and how it becomes hopefully even more useful in the future. So are there any moments that along your journey, either as a physician or even as a consultant, are there any moments that really stand out to you as affirming, "Wow, I am in the right place at the right time." [00:22:23] Amel Havkic: So it happened on, so speaking of the doctor part, yeah. It happened to me quite often. And I was first thinking of it as having bad luck. But ultimately maybe I was supposed to be there. So for some reason I run on a regular, into, into big car accidents happening. And car accidents or motorcycle accidents or so on, so forth, at least maybe 6, 7, 8 of them through, throughout my life with people really being injured and me being there as a first responder. So, so those were for instance, moments where I thought, "Okay, well, I understand this happens once or twice," but now and, and keeps keeps getting more. It's a bit maybe I wouldn't say well, it, it seems that I am supposed to be there at that time. That's how it feels to me. On the, the consulting side as well, specifically now that medtech is gaining more traction and more impact, and also with the award recently and similar things happening, that also made me feel like, "Okay, maybe I can with this make impact on more lives than just the lives I treat directly." Because if you manage to help a medtech startup launch a revolutionary idea and then survive and really make it all the way to the market and then thrive there, you impact thousands hundred, thousands, maybe millions of lives. And the, it being accepted the way it is right now is for me as well a similar sign. [00:24:05] Lindsey Dinneen: That's really cool. Yeah. I, I think, you know, I, I talk about it a lot. My role within medtech industry, you know, is, is small. I don't have that same level of impact at all. I'm, I'm helping, I'm, I'm in marketing, so I'm helping people tell their stories and get the, the word out. But I think getting to even just think about the fact that no matter kind of where you fit into the ecosystem you're helping hopefully impact patients' lives for the better and it's, it's so special getting to feel like even though it's a small role, I got to play a role. Yeah. [00:24:42] Amel Havkic: It is a, i I wouldn't even downplay it that much to be honest, because if no one hears about the solution, if no one knows that it exists there's more and more and more we're getting overloaded with all kinds of information. So, marketers who help certain things break through and reach the right people are doing their share just as anyone else in the industry is. It's maybe just as important. So yeah, I, I would encourage you to continue what you're doing up until now. [00:25:12] Lindsey Dinneen: Well, thank you. That's, that's, that is very encouraging. Okay, so, pivoting the conversation a little bit. Just for fun. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. It could be within your industry, but it doesn't have to be. What would you choose to teach? [00:25:31] Amel Havkic: Oh, that's a relatively easy one for me. I would teach clinical adoption masterclass and clinical adoption simply for the reasons we already mentioned. I would really like to help good solutions survive the reality of everyday clinical life. [00:25:50] Lindsey Dinneen: Amazing. [00:25:51] Amel Havkic: I think survive is the right, right word for this. [00:25:54] Lindsey Dinneen: Yes, I think so too, especially in having conversations with startups that are currently in the midst of this and, and trying to navigate the best approaches. So, yeah. That's incredible. Okay. And how do you wish to be remembered after you leave this world? [00:26:11] Amel Havkic: Well, that's a more difficult one. How do I wish to be remembered? Well, I would like to be the, so I would like to be the guy who everyone thinks left the world a better place than I found it. Maybe, quite short, not that extensive, but the implications are huge. You know, you can make the world better in many different ways. I do have certain skills and talents which naturally got me to where I am today. But it ultimately doesn't matter how much better the world is after I'm gone as long as it is better and this became clear to me also recently. So, while the, the awards night was going on, my wife couldn't come with me because our kid got sick, so she stayed in a hotel and, but they were watching the live stream and in the amidst of it all, when, when I came up and I went front to get the award, the little one got up, although she was sick and she was like laying in bed all day and couldn't get up. She went to the screen and pointed to the screen. So yeah, ultimately I want also my my daughter to think of me as someone who made this world a better place one way or the other. [00:27:29] Lindsey Dinneen: Yeah. I love that. That's a beautiful legacy and yeah, you're, you're doing just that, so that's amazing. That is so amazing. Okay. Okay. And then final question, what is one thing that makes you smile every time you see or think about it? [00:27:48] Amel Havkic: Oh, that's also an easy one for me. It's definitely my daughter, also my wife. It's, yeah, it's an amazing it's, it's amazing just seeing her growing up and develop all of these new skills and all of the new things that you didn't, that she didn't know how to do the day before. Also the way she goes through the world. She's fascinated by everything. Everything around is somehow magical and new and, yeah, so she can just like sit, sit in a, in a baby carriage and look around and everything is so, so awesome. She doesn't even need more. And that makes me remember that we actually should be more, way more, way more aware of the world around us and maybe not so, rushing all the time. [00:28:39] Lindsey Dinneen: Mm-hmm. Yes. I, I love that. I think I think about this sometimes of the idea of everyday magic, and those are just those moments of, I don't know, a butterfly, you know, flying by and you just see how beautiful its wings are or, you know, nature is, is very much that way for me in general. I, I, you know, you go on a walk and you go, "Oh my gosh, you know, those, those daffodils weren't there yesterday, and how beautiful are these things?" And to me, that's everyday magic. [00:29:09] Amel Havkic: Well, it, it is, and we, I, I do think that we don't take enough time to appreciate it. With always being busy with what's in the future, where we have to be and what we still have to do, that we maybe forget sometimes to appreciate what's right in front of us. [00:29:25] Lindsey Dinneen: Yeah. Yeah. I love that. Well, this has been a wonderful conversation. I'm so thankful you joined me today. Thanks for sharing your time and your experience and your stories. We are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support, and also thank you for continuing to work to change lives for a better world. We're grateful, and I wish you the most amazing continued success. [00:30:06] Amel Havkic: Thank you so much. It was a pleasure being here and looking forward to part two. [00:30:12] Lindsey Dinneen: Yeah. There you go. Alright, well thanks again and we'll talk again later. [00:30:20] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.
Full show notes: https://bengreenfieldlife.com/dralbert In this episode, Dr. Pradeep Albert breaks down the science behind HarmonIQ, formerly Hapbee, a wearable wellness company using frequency-based technology to help you access specific physiological states on demand, from deeper sleep and sharper focus to stress reduction and addiction support, all without ingesting anything. This episode also marks the official launch of HarmonIQ and its new pet-focused line Hapbee Pets. You'll discover why quality sleep without pills is the non-negotiable foundation on which every advanced longevity therapy sits, what Dezawa MuseCells are doing to cartilage and bone in professional athletes who would otherwise be facing surgery, and where CAR T-cell therapy is headed over the next decade. You'll also gain insights into peptide stacks including LL-37, ipamorelin, tessamorelin, MOTS-c, PT-141, cerebrolysin, and GHK-Cu, and what the recent FDA reclassification of 14 peptides back to Category 1 means for anyone currently using or considering them. Dr. Pradeep Albert, MD, DABR, is a board-certified musculoskeletal radiologist, author, and internationally recognized thought leader in regenerative medicine and longevity science. Over three decades, he has performed thousands of regenerative procedures, treated professional athletes across the NFL, MLB, NBA, and NHL, published over 50 peer-reviewed articles, and shaped peptide and stem cell legislation across multiple countries including advising heads of state on healthcare policy. He is the CEO of Vesalius Longevity Labs, founder of the American Academy of Peptide Medicine, and creator of RadSherpa, an AI-powered diagnostic platform now deployed in 89 countries. Save $50 on your HarmonIQ Limitless Neckband and Hapbee Pets Pad (discount auto-applied). Episode Sponsors Fatty15: Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/BEN and using code BEN at checkout. Hiya: Give your kids the full-body nourishment they need to grow into healthy adults. I’ve secured a special deal with Hiya on their best-selling children's vitamin—get 50% off your first order today! To claim this deal, you must go to hiyahealth.com/BEN (it is not available on their regular website). Young Goose: To experience the transformative power of Young Goose's cutting-edge skincare products, visit younggoose.com and use code BGF10 at checkout to enjoy a 10% discount on your order. Quantum Upgrade: Recent research has revealed that the Quantum Upgrade was able to increase ATP production by a jaw-dropping 20–25% in human cells. Unlock a 15-day free trial with the code BEN15 at quantumupgrade.io. Pendulum: Metabolic Daily is a powerful multi-strain probiotic that improves your metabolism, reduces sugar cravings, breaks down carbs more efficiently, and sustains your energy levels. You’ll receive 20% off your first month of any Pendulum probiotic with code BEN at PendulumLife.com.See omnystudio.com/listener for privacy information.
I've brought together some of my best conversations on menopause and perimenopause with Dr. Jessica Shepard, Dr. Vonda Wright, and my wife Sage. Covering why your "normal" labs miss it, how a frozen shoulder can signal hormone changes, and the truth about hormone therapy. If you're navigating midlife, this video is for you. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Connect with Dr. Jessica Shepherd Website: https://bit.ly/3Pf6ZHG YouTube: https://bit.ly/47La74k Instagram: https://bit.ly/3NG17Xu TikTok: https://bit.ly/416VYLb Facebook: https://bit.ly/4ryjyeE X.com: https://bit.ly/4192QaQ LinkedIn: https://bit.ly/3Nhrm6x Connect with Dr. Vonda Wright Website: https://bit.ly/439JGmN YouTube: https://bit.ly/43EDGTe Instagram: https://bit.ly/47UjwHl TikTok: https://bit.ly/3X7Mcq2 Facebook: https://bit.ly/3JGqEhi X.com: https://bit.ly/4oiKJt1 LinkedIn: https://bit.ly/3Lj4T7K Connect with Sage Workinger-Brecka Instagram: https://bit.ly/44sN390 Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp CYMBIOTIKA: "ULTIMATE10" FOR 10% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TAB: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8foX: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of Show 04:23 - Perimenopause begins in your late 30s 05:16 - Why hormone symptoms don't show on labs 06:55 - The earliest warning signs to watch for 11:38 - Why the whole picture matters more than one number 13:33 - Frozen shoulder reversing after hormone therapy 13:46 - The misquoted study and the FDA reversal 15:37 - Good, better, best: when to start 20:11 - Frozen shoulder as a midlife inflammation sign 23:35 - Dispelling the estrogen and breast cancer myth 24:14 - Why estrogen affects every tissue in the body 29:44 - What "natural" hormone therapy really means 32:37 - Vaginal and facial estrogen, and collagen loss 35:31 - New data in 120 million women 37:59 - Sage's story: brain fog and frozen shoulder 43:31 - Reading the Dutch test results 46:36 - When mold and toxins muddy the picture 48:27 - Three weeks later: everything changed 52:37 - Don't let anyone say it's in your head Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions. Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and/or Gary Brecka directly or indirectly holds an economic interest or receives compensation. Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices
So who wins? The CDC/FDA? Or Bill Gates? The billionaire "philanthropist" testifies before a House committee about his relationship with Jeffrey Epstein. Listen to how helpful Gates suddenly is to be of assistance in such a critical time for victim justice. The walls close in on the CDC and FDA after Senator Ron Johnson reveals both agencies knew by March of 2021 that the "vaccine" they were pushing on the world were neither safe nor effective.
We're dropping this bonus episode because something genuinely historic happened in oncology and we couldn't wait until our regular schedule to talk about it. Dr. Mark Lewis, GI medical oncologist, pancreatic cancer survivor, and one of our absolute favorite guests. He just got back from ASCO, the Super Bowl of oncology, where a new drug called daraxonrasib received one of only about six standing ovations in the conference's history, including applause that broke out mid-sentence when researchers showed the survival data on-screen. The drug targets a mutation that drives the vast majority of pancreatic cancer and has been considered "undruggable" for decades and it works not by attacking the mutation directly, but by cutting off the downstream signals it sends, like snipping the wire instead of fighting with the switch. The results are remarkable. In patients who had already received standard chemotherapy, daraxonrasib roughly doubled survival time and delivered it in pill form rather than an IV every two weeks, a meaningful quality-of-life difference for people who are already facing the hardest year of their lives. Mark walks us through the science, the side effects (rash, because RAS proteins live in skin too), the path to FDA approval, and what this means beyond pancreatic cancer, the same KRAS mutations show up in about 30% of lung cancers and 40% of colon cancers. Takeaways: Pancreatic cancer has been devastatingly hard to treat, 85% of patients are incurable at diagnosis because it spreads silently and there's no good screening, leaving most patients with a median survival of about a year on IV chemotherapy. KRAS, the mutation driving nearly all pancreatic cancer, was long considered "undruggable", the protein was so smooth and spherical that no drug could bind to it, and researchers were actively discouraged from pursuing it as a target. Daraxonrasib works by cutting the power rather than fighting the switch, instead of binding to the KRAS protein itself, it uses molecular glue to interrupt the downstream growth signals the mutation sends, an approach that took decades to develop and wasn't taken seriously until now. The trial results roughly doubled survival and the treatment is a daily pill, not an IV, patients who had already been treated with chemotherapy gained approximately an additional year of life with improved quality of life, which represents one of the most significant advances in pancreatic cancer treatment in decades. This breakthrough has implications far beyond the pancreas, KRAS mutations drive about 30% of lung cancers and 40% of colon cancers too, and proving the target is druggable opens the door to a new generation of treatments across multiple cancer types. Want more Dr. Mark Lewis? X: @marklewismd To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! – http://www.patreon.com/glaucomflecken Also, be sure to check out the newsletter: https://glaucomflecken.com/glauc-to-me/ If you are interested in buying a book from one of our guests, check them all out here: https://www.amazon.com/shop/dr.glaucomflecken If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact. For more information go to Anatomy Warehouse DOT com. Link: https://anatomywarehouse.com/?aff=14 Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit http://www.EyelidCheck.com for more information. Produced by Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices
Tim Conway Jr Show Hour 3 (6.10) Conway kicks off the hour with chaos at Hersheypark, where dozens of kids and teens are now facing charges after a massive opening-day brawl. With simple assault, riot, theft, disorderly conduct, and more in the mix, the crew asks: what happened to just riding roller coasters and eating chocolate? Then it is time for Nurse Bellio’s Medical Report, covering a possible breakthrough for Type 1 diabetes, new concerns about smartphones and declining fertility rates, the FDA approving the first new sunscreen ingredient in more than 25 years, and why strength training may be one of the best things you can do as you age. Plus, a hidden gem: Penryn Grill, tucked inside a 76 gas station in Placer County, serving upscale comfort food with a patio, fire pits, craft beer, and garden-grown ingredients. Later, the crew dives into Knicks vs. Spurs Game 4 and the shocking rise of billionaire wealth, with the world’s ultra-rich hitting historic financial highs while regular workers feel the squeeze. Then New York goes wild as the Knicks pull off a historic NBA Finals comeback, erasing a 29-point deficit to beat the Spurs 107-106 and take a 3-1 series lead. The hour wraps with a classic L.A. moment: a DUI suspect pursuit lighting up the streets. Trending Keywords: Hersheypark brawl, theme park fight, Nurse Bellio, Type 1 diabetes breakthrough, sunscreen FDA, smartphone fertility, strength training, Penryn Grill, Knicks vs Spurs, NBA Finals, Knicks comeback, billionaire wealth, L.A. pursuit, DUI suspect, Conway Show, funny podcast See omnystudio.com/listener for privacy information.
Amye is joined by Kyla to discuss Hollywood Demons S2:EP5 Surviving 16 & PregnantExpecting teens met unexpected backlash after appearing on the controversial MTV show, "16 and Pregnant"; sixteen years since the show's debut, cast members open up about the struggles they faced in its wake, including homelessness, addiction, an FBI raid, and insinuations of murder.GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.
What if your sex toy belonged on a doctor's shelf? Cynthia, founder of Luxxxe Toys, joins us for a conversation that's equal parts eye-opening and empowering. We dig into why pleasure and sexual wellness aren't just connected; they're inseparable. From the gaps in women's health research to why quality matters for what goes on and in your body, Cynthia keeps it refreshingly real. Plus: AVN, award-winning products, healing after trauma, and the conversation your doctor probably isn't having with you but should be.Use code JORDANDNELLE for a 30% listener discount. Expires July 31, 2026.✨ *Special Offers:* ✨*Splash Blanket!* Use code *Jordan15* to save 15%*ProDx Health* Use *JordanDnelle* to save 25%Thank you to our Sponsors: Splash Blanket, Prodx, PhexxJump to the Good Stuff:05:03 – From real estate to sexual wellness founder07:12 – Why pleasure and wellness are inseparable09:51 – The gaps in women's health research19:50 – AVN recap - what surprised Cynthia most25:15 – The award-winning Jaxon prostate massager30:34 – Luxury vs. budget toys - does it matter?34:10 – Surviving sexual abuse and healing through pleasure37:48 – First-time toy advice for the bedroom40:33 – What Cynthia wants to normalize next43:25 – How do you define pleasure?Pleasure Highlights:Pleasure is a health necessity, not a luxury.Women's bodies are understudied and we deserve better.The right products can support sexual healing.Toys enhance. They don't replace.Your body deserves clean, medical-grade quality.Connect with Cynthia:Instagram @luxx_toys https://www.instagram.com/luxx_toys/ https://www.luxxxe.com/Enhance your self-awareness by acknowledging and understanding your behavior patterns, and foster a deeper connection with your inner self. Get the Unleashing My Power: A Women's Empowerment and Gratitude Journal to reclaim your power through daily gratitude. Learn more HERE. Connect with Jordan D'Nelle:Facebook @jordandnelle Instagram @jordandnelle Instagram @TheVVVPodcastTikTok @jordandnelleYoutube @jordandnellewww.jordandnelle.comEmail: JordanDnelle@VaginasVulvasandVibrators.comLove this Episode?Join the Patreon: patreon.JordanDnelle.comLeave a review on iTunes.Subscribe & Follow on socials!Listen and Subscribe to the Podcast:Apple PodcastsSpotify Podcasts:Youtube @jordandnelle*Disclaimer: This podcast is for informational and/or entertainment purposes only and is not a substitute for medical advice, diagnosis, or treatment. The views and opinions expressed are my own, or those of my guests, and do not necessarily reflect the views of any organizations or institutions with which I am affiliated.Vaginas, Vulvas, and Vibrators — normalizing pleasure, bodies, and sexual health through expert, shame-free conversations.PhexxINDICATIONPhexx® is an on-demand prescription birth control used to prevent pregnancy. Phexx is not effective when used after sex.IMPORTANT SAFETY INFORMATIONRare cases (0.36%) of bladder and kidney infection have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexx.Contact your healthcare provider if you are experiencing genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis.Phexx does not protect against any sexually transmitted infections, including HIV. Avoid using Phexx with a vaginal ring.Avoid Phexx if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the Ingredients in Phexx. Stop using Phexx If you develop an allergic reaction.For more information about Phexx, talk to your healthcare provider and see full Product Informationat www.phexx.com.Please report side effects by contacting Evofem Biosciences® toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.EVFM-PHX-000068
Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results. Read more about this abstract on the AAN website. Show transcript: Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.
Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results. Read more about this abstract on the AAN website. Show transcript: Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.
I do stair climbing indoors in bad weather instead of walking outdoors. Is this worthwhile?The FDA no longer recommends use of radiation shields during X-ray procedures. What say you?I have a queasy stomach feeling, and my blood sugar is higher than usual. What are your thoughts?I've been using magnesium taurate to control palpitations and find I need more than usual.A comment about performance-enhancing drugs in professional sports
"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South. On this episode of Raise the Line from Elsevier, Bussey provides illuminating examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most. Mentioned in this episode: Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
AI regulation in the United States is at an inflection point. A new executive order, emerging legislation, and shifting political dynamics are rapidly reshaping the policy landscape for AI developers and adopters. In this episode of The Data Chronicles, we examine the administration's latest executive order on AI innovation and security, which introduces a voluntary framework for pre-release review of frontier AI models – an approach some compared to FDA-style oversight. We also explore how it differs from prior safety-focused directives and more aggressive regulatory models abroad. The discussion highlights what this moment means for companies across the ecosystem, from major tech firms helping shape policy to startups navigating commercialization. At the core is a key tension: policymakers are unusually open to new ideas but the window to influence these frameworks may be narrower than it appears.
Artificial intelligence is transforming healthcare, but developing an AI medical device is only part of the challenge. Manufacturers must also navigate certification requirements and maintain safety and performance throughout the entire product lifecycle.In two podcast episodes featuring Sandy Wright and Osman El-Koubani, we explore the journey from certifying LLM-driven medical devices to managing them after CE marking.Certifying LLM-Driven Medical DevicesLarge Language Models such as ChatGPT, Gemini, and Claude introduce new regulatory challenges. Unlike traditional software, these systems raise questions around predictability, validation, traceability, supplier management, and model updates.Topics discussed include:What defines an LLM-driven medical deviceClinical evaluation strategiesDemonstrating clinical benefitUsing commercial AI modelsSupplier controls and external dependenciesSignificant changes and model updatesLife After CE MarkingObtaining CE certification is not the end of the journey.AI medical devices require continuous monitoring once they reach the market.Manufacturers must address:Performance drift in real-world settingsCollection and analysis of real-world dataAI retraining and change managementPredetermined Change Control Plans (PCCPs)Post-Market Surveillance (PMS)Continuous safety and performance evaluationAI Devices Require a Lifecycle ApproachAI systems are dynamic technologies. Success depends not only on achieving certification, but also on maintaining control over performance, updates, and clinical safety throughout the product lifecycle.As regulations continue to evolve, manufacturers must combine robust development practices with proactive post-market monitoring to ensure long-term compliance and patient safety.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more. If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkSandy LinkedIn: https://www.linkedin.com/in/wrightsandy/Osman Linkedin: https://www.linkedin.com/in/osman-kan/Scarlet Linkedin: https://www.linkedin.com/company/scarlet-comply/posts/?feedView=all&viewAsMember=trueSocial Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.
What if the most talked-about healing peptide in biohacking came from your own stomach — and carried a risk nobody in the space is talking about?BPC-157, nicknamed "the Wolverine Peptide," has taken over fitness forums, longevity podcasts, and regenerative medicine circles. The preclinical data on tissue repair is remarkable. But the same biological mechanism that drives its healing power is the exact mechanism tumors use to survive and grow.BPC-157 is a synthetic 15 amino acid sequence isolated from human gastric juice, first identified in the early 1990s. It drives tissue repair through six mechanisms: angiogenesis via VEGF upregulation, nitric oxide pathway modulation, FAK paxillin signaling activation, growth hormone receptor upregulation in tendons and ligaments, anti-inflammatory cytokine downregulation, and free radical scavenging for cell protection. An active Phase II randomized controlled trial is currently evaluating BPC-157 for acute hamstring muscle strain repair. Its pro-angiogenic properties raise a theoretical cancer risk in individuals with undiagnosed early-stage tumors. WADA has banned it for competitive athletes. The FDA has reclassified its availability and the FDA Pharmacy Compounding Advisory Committee is reviewing its status on the approved bulk substances list.Dr. Joy Kong talks about:00:00 Meet The Wolverine Peptide02:40 Discovered Inside Human Gastric Juice03:42 Six Pathways That Drive Healing07:33 The First Real Human Trial07:58 Why The FDA Cracked Down09:24 The Hidden Cancer RiskAdditional Resources:✨ Visit My Clinic: Chara Health
Funding novel therapeutics isn't just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and startup hurdles higher than most founders realize.Michael Rome, Managing Director at Foresite Capital, joined the Smart Biotech Scientist Podcast to dissect what's really driving funding decisions today, and what early-stage founders must do to stand out.Key topics discussed:The financial cycle of biotech investment before, during, and after the COVID-19 boom (02:47)Why investors are now focused on clear pathways to approved drugs and how founders should frame their proposals (06:10)The evolving importance of CMC expertise and manufacturing readiness for startups at different stages (07:44)Leadership traits and execution qualities investors appreciate in biotech founders and teams (09:18)Promising scientific and market areas including small molecule oncology, degraders, and heterobifunctional molecules (11:24)Practical advice for founders preparing for fundraising: focusing on unmet medical needs and market analysis (14:55)The impact of recent M&A activity and regulatory challenges at the FDA on the future of biotech investment (16:27)The importance of open communication and collaboration between scientists and investors (18:47)Smart insight: For those preparing their next fundraising push, Michael advised:Start with the end in mind: Outline the unmet need, the clinical and market pathway, and the product vision firstReverse engineer your innovation: Work backwards from market and regulatory needs to inform your technical approach, not the other way around.Frame your business case: Make it obvious to investors how your solution advances value in the ecosystemIf you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee HoEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannConnect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.comNext: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show
The U.S. carried out strikes against Iran after President Trump blamed Tehran for downing a U.S. Army helicopter. The Wall Street Journal’s Shelby Holliday details the dramatic rescue of two U.S. soldiers that followed. Election betting is on track for record highs this cycle, and the prediction markets are dealing with a surge of insider trading. Reuters’s Douglas Gillison walks through the cases already emerging. Dozens of families who were separated during the first Trump administration have been separated again, despite a landmark settlement meant to reunify them. Garance Burke of the Associated Press tells us the story of one of those families. Plus, the House passed Republicans’ $70 billion immigration bill, the FDA approved the first new U.S. sunscreen ingredient in nearly two decades, and how the Knicks’ playoff run is making MSG Sports shareholders very rich. Today’s episode was hosted by Gideon Resnick.
Acne is often treated like a surface problem, but what if your skin is actually signaling deeper imbalances inside the body? On this episode of Vitality Radio, Jared breaks down acne from a functional medicine perspective, exploring how hormones, liver function, gut health, stress, blood sugar, and the microbiome may all play a role in breakouts at every age. He discusses the connection between insulin, androgen balance, endocrine-disrupting chemicals, and inflammation, while also diving into the gut-skin axis and the importance of liver detoxification pathways. Jared also shares natural strategies he has used successfully for years, including targeted nutrition, probiotic support, endocrine detoxification support, and topical approaches that work with the skin rather than against it. Plus, he offers an honest discussion about Accutane, antibiotics, and why addressing root causes matters for long-term skin health.Products:LiverVitalityEndoCleanseBack On TractPrecision Probiotic Vital SporesTriple Action Nano-Silver Skin GelVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
© 2020-2026 Ivy Podcast Discovery LLC
